Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EYENNASDAQ:IMUXNASDAQ:VACCNASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYENEyenovia$9.02+64.6%$2.22$0.85▼$124.80$15.80M11.14 million shs41.78 million shsIMUXImmunic$0.71$0.92$0.56▼$2.11$67.84M1.48951,894 shs14.11 million shsVACCVaccitech$0.88-0.6%$1.57$1.64▼$5.10$34.05M-0.4244,643 shs11,110 shsXLOXilio Therapeutics$0.66-1.4%$0.78$0.62▼$1.70$34.69M-0.011.41 million shs625,920 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYENEyenovia+64.60%+29.41%+409.60%+615.87%-83.04%IMUXImmunic0.00%-7.75%-22.84%-41.00%-35.64%VACCVaccitech+5.69%-2.31%+35.93%-13.27%-32.65%XLOXilio Therapeutics-1.43%-0.71%-25.28%-9.89%-29.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEYENEyenovia0.4844 of 5 stars1.02.00.00.02.90.00.6IMUXImmunic3.1014 of 5 stars3.63.00.00.02.62.50.6VACCVaccitechN/AN/AN/AN/AN/AN/AN/AN/AXLOXilio Therapeutics3.6683 of 5 stars3.55.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEYENEyenovia 2.00Hold$2.00-77.83% DownsideIMUXImmunic 3.25Buy$11.601,538.42% UpsideVACCVaccitech 0.00N/AN/AN/AXLOXilio Therapeutics 3.00Buy$4.00505.69% UpsideCurrent Analyst Ratings BreakdownLatest IMUX, VACC, EYEN, and XLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/29/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $10.005/23/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $5.005/16/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/1/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/30/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/16/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/15/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/10/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/1/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEYENEyenovia$60K432.96N/AN/A($695.52) per share-0.01IMUXImmunicN/AN/AN/AN/A$0.20 per shareN/AVACCVaccitech$13.42M2.54$0.05 per share19.30$6.52 per share0.14XLOXilio Therapeutics$9.27M3.69N/AN/A$0.40 per share1.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEYENEyenovia-$49.82M-$58.40N/AN/AN/A-62,238.41%-1,108.24%-316.90%8/11/2025 (Estimated)IMUXImmunic-$100.51M-$1.23N/AN/AN/AN/A-326.95%-181.34%8/6/2025 (Estimated)VACCVaccitech$5.34M-$1.43N/AN/AN/A-409.18%-23.41%-20.85%N/AXLOXilio Therapeutics-$58.24M-$0.84N/AN/AN/A-585.54%-262.69%-64.01%8/14/2025 (Estimated)Latest IMUX, VACC, EYEN, and XLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025EYENEyenovia-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million5/15/2025Q1 2025IMUXImmunic-$0.25-$0.25N/A-$0.25N/AN/A5/13/2025Q1 2025XLOXilio Therapeutics$0.10-$0.18-$0.28-$0.18$42.00 million$2.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEYENEyenoviaN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/AVACCVaccitechN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEYENEyenovia0.580.340.34IMUXImmunicN/A0.740.74VACCVaccitechN/A15.2615.26XLOXilio TherapeuticsN/A1.961.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEYENEyenovia25.84%IMUXImmunic51.82%VACCVaccitech26.13%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipEYENEyenovia7.10%IMUXImmunic4.60%VACCVaccitech6.00%XLOXilio Therapeutics6.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEYENEyenovia402.88 million2.68 millionOptionableIMUXImmunic7095.82 million91.41 millionOptionableVACCVaccitech3338.55 million36.23 millionNot OptionableXLOXilio Therapeutics7051.78 million48.52 millionNot OptionableIMUX, VACC, EYEN, and XLO HeadlinesRecent News About These CompaniesJames Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) StockJune 19, 2025 | insidertrades.comXilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest UpdateJune 16, 2025 | americanbankingnews.comXilio Therapeutics expands board, elects new directorJune 13, 2025 | investing.comXilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of DirectorsJune 10, 2025 | quiverquant.comXilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of DirectorsJune 10, 2025 | globenewswire.comXilio Therapeutics Announces Closing of $50.0 Million Public OfferingJune 5, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 | globenewswire.comXilio Therapeutics Announces Pricing of $50.0 Million Public OfferingJune 2, 2025 | globenewswire.comXilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite ...June 2, 2025 | stockhouse.comXilio Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Pre-Funded Warrants and Series A, B, and C WarrantsJune 2, 2025 | quiverquant.comXilio Therapeutics Announces Proposed Public OfferingJune 2, 2025 | globenewswire.comXilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug TrialMay 31, 2025 | insidermonkey.comXilio Therapeutics Reports Preliminary 26% Objective Response Rate in Phase 2 Trial of Vilastobart Combined with Atezolizumab for Metastatic MSS Colorectal CancerMay 31, 2025 | quiverquant.comXilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal CancerMay 31, 2025 | globenewswire.comXilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial ResultsMay 8, 2025 | finanznachrichten.deXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial ResultsMay 8, 2025 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comXilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual MeetingApril 23, 2025 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUX, VACC, EYEN, and XLO Company DescriptionsEyenovia NASDAQ:EYEN$9.02 +3.54 (+64.60%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$8.83 -0.19 (-2.11%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Immunic NASDAQ:IMUX$0.71 0.00 (0.00%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$0.74 +0.03 (+3.95%) As of 04:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Vaccitech NASDAQ:VACCVaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Xilio Therapeutics NASDAQ:XLO$0.66 -0.01 (-1.43%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$0.66 +0.00 (+0.55%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
